Abeona Therapeutics Inc (ABEO)vsBeiGene, Ltd. (ONC)
ABEO
Abeona Therapeutics Inc
$4.42
+2.08%
HEALTHCARE · Cap: $241.15M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 91705% more annual revenue ($5.34B vs $5.82M). ABEO leads profitability with a 12.2% profit margin vs 5.4%. ABEO trades at a lower P/E of 3.7x. ABEO earns a higher WallStSmart Score of 43/100 (D).
ABEO
Hold43
out of 100
Grade: D
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+38.5%
Fair Value
$8.23
Current Price
$4.42
$3.81 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 70 in profit
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 100.0%
Negative free cash flow — burning cash
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABEO
The strongest argument for ABEO centers on P/E Ratio, Return on Equity, Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : ABEO
The primary concerns for ABEO are EPS Growth, Market Cap, Revenue Growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
ABEO profiles as a declining stock while ONC is a hypergrowth play — different risk/reward profiles.
ABEO carries more volatility with a beta of 1.19 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ABEO scores higher overall (43/100 vs 42/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abeona Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?